ADOPT was a pragmatic, real-life, double-blind, randomised multicentre study which was evaluating specifically whether thiazolidinediones, with their different mode of action, can provide more durable glycaemic control than metformin or sulphonylureas. By utilising a monotherapy approach, in people with T2DM diagnosed for less than three years who are antihyperglycaemic agent naïve, ADOPT was designed to compare the relative efficacy of these three oral agents as judged primarily by the time to monotherapy failure. ADOPT will provide data on the effect of mechanistically differing treatment options on metabolic control, beta cell function, and markers of macrovascular disease risk in type 2 diabetes.
The ADOPT results were announced at the IDF 19th World Diabetes Congress in Cape Town on Monday 4th December at 16.30 local time and simultaneously published in the New England Journal of Medicine.
ADOPT (A Diabetes Outcomes Prevention Trial) showed that initial treatment with just rosiglitazone provided more durable glycemic control than metformin or glyburide in patients with recently diagnosed type 2 diabetes. In CJASN, we examine the differences in albumin excretion, renal function and blood pressure over the course of 5 years between the treatment groups....[Read more...]
The ADOPT study (A Diabetes Outcomes Prevention Trial) showed that treatment with rosiglitazone alone provided somewhat more effective glycaemic control than metformin or glyburide alone, in patients with recently diagnosed type 2 diabetes. In a paper published recently in Diabetes, we examined changes in β-cell function and insulin sensitivity among the three treatments in ADOPT....[Read more...]
Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin over Four-Years in Spite of Greater Weight Gain: Observations from ADOPT (A Diabetes Outcome Progression Trial).